Antiproliferative effect of metformin on the endometrium - A clinical trial

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 23, 2014, Pages 10067-10070

  Tabrizi, Ali Dastranj ^a   Melli, Manijeh Sayyah ^a   Foroughi, Meraj ^a   Ghojazadeh, Morteza ^a   Bidadi, Sanam ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anti estrogenic influence; Endometrial atrophy; Endometrial hyperplasia; Mestrol; Metformin

Indexed keywords

ANTIDIABETIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; MEGESTROL ACETATE; METFORMIN;

ADULT; ATROPHY; COMPLICATION; CONTROLLED STUDY; ENDOMETRIAL HYPERPLASIA; ENDOMETRIOID CARCINOMA; ENDOMETRIUM; ENDOMETRIUM TUMOR; FEMALE; HUMAN; METRORRHAGIA; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; ATROPHY; CARCINOMA, ENDOMETRIOID; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MEGESTROL ACETATE; METFORMIN; METRORRHAGIA;

EID: 84921757756     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.23.10067     Document Type: Article

References (28)

1. Acmaz G, Aksoy H, Albayrak E, et al (2014). Evaluation of endometrial precancerous lesions in postmenopausal obese women-a high risk group? Asian Pac J Cancer Prev, 15, 195-8.
2. Avci CB, Harman E, Dodurga Y, Susluer SY, Gunduz C (2013). Therapeutic potential of an anti-diabetic drug, metformin: alteration of miRNA expression in prostate cancer cells. Asian Pac J Cancer Prev, 14, 765-8.
3. Chao A, Lin CY, Tsai CL, et al (2013). Estrogen stimulates the proliferation of human endometrial cancer cells by stabilizing nucleophosmin/B23 (NPM/B23). J Mol Med (Berl), 91, 249-59.
4. Campagnoli C, Abba C, Ambroggio Set al (2013). Life-style and metformin for the prevention of endometrial pathology in postmenopausal women. Gynecol Endocrinol, 29, 119-24.
5. Eftekhar Z, Izadi-Mood N, Yarandi F, et al (2009). Efficacy of megestrol acetate (Megace) in the treatment of patients with early endometrial adenocarcinoma: our experiences with 21 patients. Int J Gynecol Cancer, 19, 249-52.
6. Fryer LG, Parbu-Patel A, Carling D (2002). The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem, 277, 25226-32.
7. Huang X, Wellschleger S, Shapiro N, et al (2008). Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J, 412, 211-21.
8. Hardie DG (2003). The AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology, 144, 5179-83.
9. Jarboe EA, Mutter GL (2010). Endometrial intraepithelial neoplasia. Semin Diagn Pathol, 27, 215-25.
10. Ko EM, Walter P, Jackson A, et al (2014). Metformin is associated with improved survival in endometrial cancer. Gynecol Oncol, 132, 438-42.
11. Libby G, Donnelly LA, Donnan PT, et al (2009). New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care, 32, 1620-5.
12. Mutter GL, Zaino RJ, Baak JP, et al (2007). Benign endometrial hyperplasia sequence and endometrial intraepithelial neoplasia. Int J Gynecol Pathol, 26, 103-14.
13. Mutter GL (2000). Endometrial intraepithelial neoplasia (EIN): Will it bring order to chaos? Gynecol Oncol ,76, 287-290.
14. Mutter GL, Baak JPA, Crum CP, et al (2002). Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry. J Pathol, 190, 462-9.
15. Nevadunsky NS, Van Arsdale A, Strickler HD, et al (2013). Metformin use and endometrial non endometriod cancer survival. Gynecol Oncol, 132, 236-40.
16. Navaratnarajah R, Pillay OC, Hardiman P (2008). Polycystic ovary syndrome and endometrial cancer. Semin Reprod Med, 26, 62-71.
17. Prat J, Bentley RC, Russel P, Anderson MC (2009). Endometrial intraepithelial neoplasia. In 'Robboy's Pathology of Female Reproductive Tract', Eds. Elsevier, China, pp 367-397.
18. Perino A, Quartararo P, Catinella E, et al (1987). Treatment of endometrial hyperplasia with levonorgestrel releasing intrauterine devices. Acta Eur Fertil, 18, 137-40.
19. Randall TC, Kurman RJ (1997). Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol, 90, 434-40.
20. Sarfstein R, Friedman Y, Attias-Geva Z, et al (2013). Metformin down regulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or-independent manners. PLoS One, 19, 61537.
21. Shen ZQ, Zhu HT, Lin JF. (2008). Reverse of progestin-resistant atypical endometrial hyperplasia by metformin and oral contraceptives. Obstet Gynecol, 112, 465-7.
22. Shafiee MN, Khan G, Ariffin R, et al (2013). Preventing endometrial cancer risk in polycystic ovarian syndrome (PCOS) women: Could metformin help? Gynecol Oncol, 13, 1277-8.
23. Thigpen JT, Brady MF, Alvarez RD, et al (1999). Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol, 17, 1736-44.
24. Tas M, Kutuk MS, Serin IS, et al (2013). Comparison of antiproliferative effects of metformine and progesterone on estrogen-induced endometrial hyperplasia in rats. Gynecol Endocrinol, 29, 311-4.
25. van Meurs HS, Bleeker MC, van der Velden J, et al (2013). The incidence of endometrial hyperplasia and cancer in 1031 patients with a granulosa cell tumor of the ovary: long-term follow-up in a population-based cohort study. Int J Gynecol Cancer, 23, 1417-22.
26. Wheeler DT, Bristow RE, Kurman RJ (2007). Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins. Am J Surg Pathol, 31, 988-98.
27. Zhou G, Myers R, Li Y, et al (2001). Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest, 108, 1167-74.
28. Zakikhani M, Dowling R, Fantus IG, et al (2006). Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res, 66, 10267-73.